On Frank Carter, US Army Lieutenant Colonel, Remdesivir casualty, and what to do about it.

This is an article on a Remdesivir protocols murder case in Nashville, Tennessee.  The family wants to pursue criminal charges.  No Attorney General in the United States has yet to take a stand against this murder program that simulated the spread of a deadly virus.   

In order to make Prosecutors take a stand, I think it is necessary to do the investigative work for them as best you possible can, then take it to them. 

What follows are some of the basic facts of Frank’s case as reported by his wife and daughter in a November 12, 2022 Claryfication podcast, hosted by James Clary. 

Frank was a former Lieutenant Colonel in the United States Army and was described by his family doctor as being in the best shape of any 80 year-old man he had ever seen.

Frank served in the 7th Cavalry in the United States Army in Germany on the Czech border from 1955-1958. After returning to the United States, he served in the National Guard in Tullahoma, Tennessee in the 1175th Transportation Company and in Nashville, Tennessee in the 194th Engineer Brigade. His final rank was Lieutenant Colonel.

In early April 2020, Frank Carter, age 82, and his wife, age 80, developed stomach problems.   Frank was 82, his wife was 80.  

Frank never had breathing issues associated with “Sudden Acute Respiratory Syndrome,” only some stomach problems and weakness.  Frank’s oldest daughter took him to Vanderbilt Hospital in Nashville, where he tested positive for COVID.  

At Vanderbilt, Frank and his family were told that Remdesivir was the best thing around and that people were being successfully treated with it at Vanderbilt.  Frank was admitted into a Vanderbilt clinical trials study on Remdesivir on April 7, 2020.  

Her daughter Monique asked if it was possible to use Hydroxychloroquine.  Vanderbilt told her that Hydroxychloroquine caused heart problems. ORCHID trials at Vanderbilt using Hydroxychloroquine, however, were shut down early without a safety signal. (1)

According to Frank’s medical records obtained by his daughter Peggy, her father was intubated (vented) on April 8.  He was “proned,” or placed in a face down position, on April 9, and was given a paralyzing agent. 

Vanderbilt did not allow Frank’s family to speak to him or visit him until he was near death.  He died on April 13.

The day after her husband died, the Tennessee Department of Health sent Frank’s wife a letter saying that she was not allowed to leave her home, and if she did so, that she was subject to arrest.

The family of Frank Carter believes that the protocols used on Frank were tantamount to murder.  They spoke of many other details surrounding Frank’s death in the Claryfication podcast.

RECOMMENDATIONS

In order to pursue criminal charges, the family should consider what evidence they would need to see to return a guilty verdict for homicide if they were a member of a jury hearing Frank’s case.  

I have a modest background in statistics.  If Vanderbilt Hospital had data that clearly showed that Remdesivir was causing large numbers of needless deaths, at a much higher than acceptable mortality rate, I would consider that to be strong evidence supporting a guilty verdict for the people who should have known about the data.  

Interestingly, Vanderbilt was involved in clinical trials of both Remdesivir (2). and Hydroxychloroquine (3).   They would have had the evidence of mortality rates from both protocols. Remdesivir has been widely reported to be extremely deadly, and Hydroxychloroquine has been reported to be safe and effective (despite some clinical trials that say is was ineffective, those same trials did not have the same high mortality rates as Remdesivir).   Mark Denison’s Denison Lab at Vanderbilt was also involved in developing Remdesivir (4), so they had a conflict of interest in the trials of Remdesivir and Hydroxychloroquine.  

Cutting through all the BS, how many people died at Vanderbilt? 

If I was on a Jury, I would like to see:

(A). The quantity of people given Remdesivir at Vanderbilt, and the the quantity of people who died who received Remdesivir at Vanderbilt. 

(B). The quantity of people given Hydroxychloroquine at Vanderbilt, and the the quantity of people who died who received Hydroxychloroquine at Vanderbilt.

(C).  The amount of money paid to Vanderbilt to administer Remdesivir at Vanderbilt.

(D).  The amount of money paid to Vanderbilt to administer Hydroxychloroquine at Vanderbilt.

(D).  Any royalties paid to Vanderbilt or their employees for their role in developing Remdesivir.

That is “big picture” evidence.   It could establish that hospital administrators were aware of needlessly high death rates at their hospital. It could be evidence that they put their finances first, instead of their medical duties.

In order to get the relevant statistical data, Freedom of Information requests and lawsuits will likely be required.  

If the big picture looks as bad as I fear it does, that evidence should be combined with the details of the individual case.  All of the individuals involved in the Remdesivir/Hydroxychloroquine trials at Vanderbilt should be deposed.

An effort like this will be expensive.  I recommend that the victim’s groups form a nonprofit and raise funds to support their legal needs.  I do not recommend that victims groups use lawyers working on a contingency basis.

Once you get the evidence, we’ll see what it looks like and then we can go from there.  

Charles Wright

P.S.

Please join me on Substack Notes. Remdesivir victims are not well represented in this community and need to raise your voice. Use substack.com/notes or the “Notes” tab in the Substack app.

REFERENCES

(1). Judicial Watch FOIA request.pdf

(2). Remdesivir may be a promising approach to treat advanced COVID-19 disease, according to preliminary data released by the National Institutes of Health (NIH) from an ongoing clinical trial. The international trial, which includes investigators from Vanderbilt University Medical Center, is showing that adults who received remdesivir are recovering an average of four days faster (11 days versus 15 days, a 31 percent acceleration) than patients who were given a placebo. It is only a preliminary look at the data, and additional data are expected to be available in the upcoming weeks. “This is a very large, carefully designed trial with over 1,000 patients enrolled in the U.S. and around the world. Patients were given the drug at various stages of their illness and with various levels of severity; it is definitely encouraging that we can see faster recovery even with this first look at the data,” said Vanderbilt’s principal investigator C. Buddy Creech, M.D., director of the Vanderbilt Vaccine Research Program.

(3). On April 2, 2020, Vanderbilt said that they enrolled the first patients in ORCHID. Vanderbilt University Medical Center: "The ORCHID trial ... funded by the National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health, enrolled its first patient on April 2 and will include hundreds of patients to determine if hydroxychloroquine is an effective treatment against the virus projected to hospitalize thousands of U.S. residents in the coming weeks."

(4). Vanderbilt.edu: Vanderbilt Chancellor Daniel Diermeier remarked: “The Denison Lab led the development of the COVID-19 antiviral remdesivir, which was for many months the only widely available and known treatment for COVID-19. He (Mark Denison) also was the first to show human antibody response to the Moderna vaccine,”

END